Pfizer (PFE) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to earnings of $1.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 152.63%. A quarter ago, it was expected that this drugmaker would post a loss of $0.32 per share when it actually produced a loss of $0.17, delivering a surprise of 46.88%.Over the last four quarters, the company h ...

Shares of Pfizer Inc. PFE, +0.04% gained 0.7% early Tuesday after the company beat analysts’ earnings expectations and reaffirmed its full-year 2024 guidance issued in December. The drugmaker reported a fourth-quarter net loss of $3.37 billion, or 60 cents a share, compared with net income of $4.995 billion, or 87 cents a share, in the year-earlier period. Adjusted earnings per share came to 10 cents, beating the FactSet consensus of a loss of 18 cents per share. Revenues totaled $14.249 billion in the quar ...

Pfizer CEO Albert Bourla talks during a press conference with European Commission President Ursula von der Leyen after a visit to oversee the production of the Pfizer-BioNtech COVID-19 vaccine at the factory of U.S. pharmaceutical company Pfizer in Puurs, Belgium April 23, 2021.Pfizer on Tuesday posted a surprise adjusted fourth-quarter profit, as the company slashed costs while demand for its Covid products plummeted.The company reversed roughly $3.5 billion in revenue related to the expected return of 6.5 ...

Pharmaceutical giant Pfizer on January 30th reported its financial results for Q4 and the full year of 2023.The company reported disappointing results, to say the least, including $58.5 billion in revenues for 2023 and $14.24 billion in revenues in Q4, down 42 percent and 41 percent from 2022 year-on-year. Paxlovid and Comirnaty Copy link to sectionA lot of this seemed to be due to acquisitions Paxlovid and Comirnaty, as the company said in its earnings announcement that:Expected Decline in Comirnaty and Pa ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth quarter and full-year 2023 and reaffirmed its 2024 financial guidance(5) provided on December 13, 2023. The fourth-quarter 2023 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “ We are encouraged by the strong performance ...

Pfizer (PFE) has been relying on its newly launched and newly acquired products to improve its sales performance amid a decline in revenues from its COVID-19 products.Pfizer records direct sales and alliance revenues from its partner, BioNTech (BNTX) , for the COVID-19 vaccine, Comirnaty, and product revenues from its oral antiviral pill for COVID, Paxlovid.Investors will be keen to know the sales numbers of Pfizer’s several newly launched drugs like Abrysvo, Velsipity, Penbraya, Zavzpret as well as newly a ...

Key PointsThe rotation into defensive names is here, and the healthcare stocks seem to be accumulating the bulk of employment and business activity.Pfizer offers above-average growth at a massive discount to competitors within that sector, like Eli Lilly and AstraZeneca.Analysts see the writing on the wall and aren't afraid to tell you about their price targets.5 stocks we like better than PfizerThe defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflo ...

Pfizer (PFE) has reached a major transition point. The big pharma company took center stage earlier in the COVID-19 pandemic when it became the first to launch a coronavirus vaccine. That product, Comirnaty, and the treatment Paxlovid, released later, helped Pfizer's revenue reach a record level of $100 billion in 2022; the two products made up more than half of that.Now, though, with coronavirus product demand falling and losses of exclusivity ahead for some of Pfizer's other drugs, the company's revenue i ...

Analyst Estimates for Q4 2023Q3 2023Q4 2022Revenue$14.3 billion$13.2 billion$24.3 billionAdjusted Earnings (or Loss) Per Share(19 cents)(17 cents)$1.14Adjusted Net Income (or Loss)($1.1 billion)($968 million)$6.55 billion Key Metric After Pfizer has struggled amid poor demand for its COVID-19 products, including its Paxlovid treatment and the Comirnaty vaccine, investors will want to watch for the company’s reported revenue from this segment. Analysts are projecting sales of the vaccine to fall 52% in th ...

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, “Astellas”) today announced that on January 26 the European Medicines Agency (EMA) validated for review a Type II variation application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, PADCEV with K ...